Twist Bioscience Corp (NASDAQ: TWST) shares tumbled 7.66% in pre-market trading on Friday following the release of its fiscal fourth-quarter earnings report, which revealed mixed results and provided guidance that fell short of some investors' expectations.

The synthetic DNA technology company reported a larger-than-expected loss for the quarter ended September 30, 2025. Twist Bioscience posted a net loss of $0.45 per share, missing analysts' estimates of a $0.43 loss. However, the company's revenue performance was more positive, with Q4 sales reaching $99.0 million, surpassing the consensus estimate of $97.4 million and marking a 16.88% increase from the same period last year.

Despite the revenue beat, investors appeared to focus on the company's forward-looking statements. Twist Bioscience provided guidance for the first quarter of fiscal 2026, projecting revenue between $100 million and $101 million, which aligns closely with analysts' expectations. However, the full-year fiscal 2026 revenue outlook of $425 million to $435 million may have disappointed some market participants, as it suggests a potential slowdown in growth compared to the previous year's performance. This guidance, combined with the earnings miss, likely contributed to the significant pre-market decline in Twist Bioscience's stock price.